KR930003905A - 약학적 결합 제제 - Google Patents

약학적 결합 제제 Download PDF

Info

Publication number
KR930003905A
KR930003905A KR1019920013983A KR920013983A KR930003905A KR 930003905 A KR930003905 A KR 930003905A KR 1019920013983 A KR1019920013983 A KR 1019920013983A KR 920013983 A KR920013983 A KR 920013983A KR 930003905 A KR930003905 A KR 930003905A
Authority
KR
South Korea
Prior art keywords
formulation
diltiazem
pharmaceutically acceptable
acceptable salt
film coating
Prior art date
Application number
KR1019920013983A
Other languages
English (en)
Inventor
리챠드 벅스톤 이안
브라운 아드리안
크리츨리 헬렌
토마스 레슬리에 스트워트
떼레세 안토이네트 말코우스카 산드라
알란 프라터 데렉
브라운 밀러 로널드
Original Assignee
원본미기재
유로셀티크 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 유로셀티크 에스.에이. filed Critical 원본미기재
Publication of KR930003905A publication Critical patent/KR930003905A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

내용 없음.

Description

약학적 결합 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 방출 조절형의 딜티아젬이나 약학적으로 허용가능한 이의 염과 속방출형의 하이드로클로로티아자이드를 포함하는 고체 경구 제형.
  2. 제1항에 있어서, 방출조절 성분은 딜티아젬과 약학적으로 허용가능한 이의 염으로 된 다수의 비드(bead)를 포함함을 특징으로 하는 제형.
  3. 제2항에 있어서, 딜티아젬이나 약학적으로 허용가능한 이의 염은 비드의 40중량%-98중량%의 양으로 존재함을 특징으로 하는 제형.
  4. 제2항 또는 제3항에 있어서, 방출조절 성분은 딜티아젬이나 약학적으로 허용가능한 이의염과 구상화제로 된 다수의 구상화물을 포함함을 특징으로 하는 제형.
  5. 제4항에 있어서, 구상화제는 마이크로크리스탈린 셀룰로오스 임을 특징으로 하는 제형.
  6. 제4항 또는 제5항에 있어서, 구상화제는 구상코아의 15중량%-40중량% 양으로 존재함을 특징으로 하는 제형.
  7. 제4항 또는 제6항에 있어서, 구상물은 방출 조절 필름 코팅물질로 코팅됨을 특징으로 하는 제형.
  8. 제7항에 있어서, 필름 코팅물질을 불용성 폴리머를 포함함을 특징으로 하는 제형.
  9. 제8항에 있어서, 필름 코팅물질은 에틸셀룰로오스를 포함함을 특징으로 하는 제형.
  10. 제7-9항 중의 어느 한 항에 있어서, 필름 코팅물질은 하나 또는 그 이상의 가소제, 계면활성제와 택-개량제를 포함함을 특징으로 하는 제형.
  11. 제10항에 있어서, 필름 코팅물질은 50%-95%의 에틸셀룰로오스, 5%-15%의 콜로이드성 무수 실리카, 5%-15% 디부틸 세바케이트와 5%-15%의 폴리솔 베이트80을 포함함을 특징으로 하는 제형.
  12. 제1-11항 중의 어느 한 항에 있어서, 방출조절형의 딜티아젬이나 또는 약학적으로 허용가능한 이의 염과 속방출형의 하이드로클로로티아자이드를 포함하는 외측 코팅층으로 된 코아를 포함함을 특징으로 하는 제형.
  13. 제1-12항중의 어느 한 항에 있어서, 딜티아젬이나 또는 약학적으로 허용가능한 이의 염대 하이드로클로로티아자이드의 중량비는 30 : 1-4 : 1의 범위내에 있음을 특징으로 하는 제형.
  14. 제13항에 있어서, 150㎎의 딜티아젬 염산염과 12.5㎎의 하이드로클로로티아자이드를 포함함을 특징으로 하는 제형.
  15. 제1-14항 중의 어느 한 항에 따르는 제형을 포함하는 캡슐제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920013983A 1991-08-12 1992-08-04 약학적 결합 제제 KR930003905A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919117361A GB9117361D0 (en) 1991-08-12 1991-08-12 Oral dosage form
GB9117361.7 1991-08-12

Publications (1)

Publication Number Publication Date
KR930003905A true KR930003905A (ko) 1993-03-22

Family

ID=10699854

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013983A KR930003905A (ko) 1991-08-12 1992-08-04 약학적 결합 제제

Country Status (14)

Country Link
US (1) US5508044A (ko)
EP (1) EP0527638A1 (ko)
JP (1) JPH05201866A (ko)
KR (1) KR930003905A (ko)
CN (1) CN1069191A (ko)
AU (1) AU658209B2 (ko)
CA (1) CA2075355A1 (ko)
FI (1) FI923581A (ko)
GB (1) GB9117361D0 (ko)
IL (1) IL102777A (ko)
IN (2) IN173847B (ko)
NO (1) NO300797B1 (ko)
PH (1) PH30666A (ko)
ZA (2) ZA926020B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
CN1103592C (zh) * 1996-05-22 2003-03-26 永光制药有限公司 含有2－(苯基亚氨基)－3－苯基－1,3－全氢噻嗪的药物组合物及其应用和制备方法
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
WO1999032119A1 (en) 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP2243471A1 (en) * 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
JP5351490B2 (ja) * 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
JP5845173B2 (ja) * 2009-05-01 2016-01-20 アデア ファーマスーティカルズ，インコーポレイテッド 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FI101344B (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
CA2098176C (en) * 1990-12-14 2006-12-12 Joseph Weinstock Angiotensin ii receptor blocking compositions
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation

Also Published As

Publication number Publication date
IL102777A0 (en) 1993-01-31
IL102777A (en) 1996-05-14
NO300797B1 (no) 1997-07-28
PH30666A (en) 1997-09-16
US5508044A (en) 1996-04-16
FI923581A (fi) 1993-02-13
CN1069191A (zh) 1993-02-24
ZA926020B (en) 1993-03-10
AU658209B2 (en) 1995-04-06
IN173839B (ko) 1994-07-23
NO923127L (no) 1993-02-15
NO923127D0 (no) 1992-08-11
FI923581A0 (fi) 1992-08-11
GB9117361D0 (en) 1991-09-25
ZA926019B (en) 1993-03-10
AU2087992A (en) 1993-02-18
JPH05201866A (ja) 1993-08-10
EP0527638A1 (en) 1993-02-17
CA2075355A1 (en) 1993-02-13
IN173847B (ko) 1994-07-23

Similar Documents

Publication Publication Date Title
KR930003905A (ko) 약학적 결합 제제
KR930003906A (ko) 약학적 구상 제형
EP0605174B1 (en) Delayed, Sustained-release pharmaceutical preparation
US5102668A (en) Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
DE69427568D1 (de) Rasch freisetzende Tablettenkerne mit unlöslichen Arzneistoffen und mit einem Retardüberzug
CA1303504C (en) Pharmaceutical formulation containing acrivastine
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
KR890009380A (ko) 서방성 약학제제
KR870002832A (ko) 제약 조성물
KR900015734A (ko) 코어막 흡착 특성이 향상된, 약제학적으로 허용되는 활성성분을 함유하는 삼투성 연속 방출 경구 전달 시스템
JPH08506802A (ja) 波状粒薬配給システム
NO975218D0 (no) Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer
CA2124012A1 (fr) Formulation de diltiazem a liberation prolongee
KR880000088A (ko) 지속적인 방출 제제
KR870000069A (ko) 안정한 고체 제형의 제조 방법
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
CA2021574A1 (en) Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
BRPI0309142B1 (pt) 20120040114 suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
CA1251731A (en) Sustained release tablets and method for preparation thereof
ATE79026T1 (de) Feste pharmazeutische retardform.
NZ270748A (en) Sustained release dosage form of alfuzosin hydrochloride coated with a ph-dissolution dependent polymer
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil
BG61751B1 (bg) Форма за контролирано освобождаване на лекарствена дисперсия

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application